The FDA response on the Phase 2b study design, expected by end of November 2026, is the next major catalyst. Cash runway appears tight given the $10.6M balance and rising R&D spend; watch for potential equity financing or partnership announcements to extend runway beyond early 2027.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $0.8013entry
- T+1 · 8d ago +4.82%α +2.45% · $0.8399
- T+5 · 4d ago −3.78%α −6.38% · $0.7710
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Phio Pharmaceuticals reported Q3 2026 results with a net loss of $4.2M, wider than the $2.4M loss a year ago, driven by higher R&D spending on the PH-762 program. The company completed commercial-scale cGMP manufacturing and submitted a final Phase 1b clinical study report to the FDA, with a response expected by end of November 2026. Cash burn remains high, with cash dropping to $10.6M from $21.0M at year-end 2025, raising financing concerns.
Key Facts
- Net loss of $4.2M for Q3 2026 vs $2.4M in Q3 2025, a 74% increase
- Cash and cash equivalents fell to $10.6M as of Sep 30, 2026 from $21.0M at Dec 31, 2025
- R&D expenses rose 159% to $3.0M in Q3 2026, driven by PH-762 program costs
- Final Phase 1b clinical study report submitted to FDA; response expected by end of November 2026
- First commercial-scale cGMP batch of PH-762 drug substance completed; Phase 2b initiation targeted for Q1 2027
- No revenue reported; company is a clinical-stage biotech with no approved products
Financial Impact
Net loss of $4.2M in Q3 2026, cash burn of $10.4M over nine months; cash runway likely limited given $10.6M remaining and rising R&D costs
Risk Factors
- Cash burn rate is high; $10.6M may not fund operations into H2 2027 without additional financing
- No approved products or revenue; clinical-stage biotech with binary FDA outcome risk
- Potential dilutive equity financing needed if FDA feedback delays Phase 2b or requires additional studies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-035277 |
| Document: phio20261028_8k.htm | 0001437749-26-035277 |
| Document: 0001437749-26-035277-index-headers.html | 0001437749-26-035277 |
| Document: 0001437749-26-035277-index.html | 0001437749-26-035277 |
| Document: 0001437749-26-035277.txt | 0001437749-26-035277 |
| 8-K Data (Synthetic) | 0001437749-26-035277 |
Track record
7 reports on PHIO
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago 8-K Bearish 5/10 Viewing Entry $0.8013 to $0.7710 Now $0.7520 +6.15% ▲ +3.78% +6.38% vs SPY
- Oct 13, 20264w ago 8-K Neutral 3/10 Entry $0.9345 to $0.8921 Now $0.7520 −19.53% ▼ −4.54% −3.39% vs SPY
- Sep 14, 20269w ago 8-K Bullish 5/10 Entry $1.03 to $1.01 Now $0.7520 −26.99% ▼ −1.94% −2.05% vs SPY
- Aug 14, 202613w ago DEFA14A Neutral 3/10 Entry $1.06 to $1.17 Now $0.7520 −29.06% ▲ +10.38% +11.57% vs SPY
- Apr 8, 202631w ago 8-K Neutral 5/10 Entry $1.25 to $1.27 Now $0.7520 −39.84% ▲ +1.60% −1.59% vs SPY
- Apr 8, 202631w ago 424B5 Neutral 5/10 Entry $1.25 to $1.27 Now $0.7520 −39.84% ▲ +1.60% −1.59% vs SPY
- Mar 5, 202636w ago 8-K Mixed 6/10 Entry $1.16 to $1.17 Now $0.7520 −35.17% ▲ +0.86% +2.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers